thyroid cancer
Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting
Following the initial results readout, the firm will expand the Phase I/II SWORD-1 trial and decide on a recommended Phase II dose prior to meeting with regulators.
The firm's BRAF inhibitor, PLX8394, targets cancers with non-V600 BRAF mutations that see little benefit from BRAF inhibitors currently on the market.
Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients
Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
This is the second precision oncology drug approved by the agency for patients with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.